of S961 (insulin receptor antagonist, Novo Nordisk A/S, Kalundborg, Denmark) prior to glucose solution mixed with curcumin (25, 50 mg/kg B.wt.) or DPP4i (10, 20 mg/kg B.wt.)
This means that it's not just a short-term solutionit actively aids long-term healing and wellness
This physiological effect, whilst beneficial for reducing post-prandial glucose spikes and promoting satiety, can lead to feelings of fullness, bloating, and nauseaparticularly during the initial weeks of treatment or following dose escalations
Studies show this process can take over an hour during the first month of treatment instead of just minutes
The diabetes and obesity markets are massive, but are also intensely competitive and rapidly evolving
But Pfizer appeared to be confident in the once-daily form of danuglipron back in July, when it said it would start conducting studies in the second half of the year to evaluate multiple doses of the pill